Media headlines about ANI Pharmaceuticals (NASDAQ:ANIP) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ANI Pharmaceuticals earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 46.0209374513104 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of ANI Pharmaceuticals (ANIP) opened at $67.96 on Wednesday. The company has a market cap of $791.71, a price-to-earnings ratio of 20.28 and a beta of 2.91. ANI Pharmaceuticals has a 52-week low of $42.23 and a 52-week high of $74.70. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 3.45.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. The firm had revenue of $48.16 million for the quarter, compared to the consensus estimate of $48.12 million. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The company’s revenue was up 25.0% on a year-over-year basis. During the same period last year, the firm earned $1.09 EPS. analysts anticipate that ANI Pharmaceuticals will post 3.59 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Canaccord Genuity set a $75.00 price objective on shares of ANI Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday. ValuEngine upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, November 25th. TheStreet upgraded shares of ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research report on Thursday, November 16th. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price objective on the stock in a research report on Tuesday, November 7th. Finally, BidaskClub upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 18th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $70.50.

TRADEMARK VIOLATION NOTICE: This story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with's FREE daily email newsletter.